欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2021, Vol. 26 ›› Issue (7): 787-793.doi: 10.12092/j.issn.1009-2501.2021.07.010

• 药物治疗学 • 上一篇    下一篇

1,25二羟维生素D3在脊柱结核治疗中的免疫调节作用

章权,石仕元,韩贵和   

  1. 浙江省中西医结合医院骨科,杭州 310003,浙江
  • 收稿日期:2020-06-01 修回日期:2020-10-12 出版日期:2021-07-26 发布日期:2021-08-09
  • 作者简介:章权,硕士,主治医师,研究方向:骨关节结核的诊治。 Tel: 15024412418 E-mail: zhangquanzq@sohu.com
  • 基金资助:
    杭州市科技发展计划重点专病专科项目(20160533B42)

1,25 dihydroxy vitamin D3 for immunoregulation in the treatment of spinal tuberculosis 

ZHANG Quan, SHI Shiyuan, HAN Guihe   

  1. Department of Orthopedics, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou 310003, Zhejiang, China
  • Received:2020-06-01 Revised:2020-10-12 Online:2021-07-26 Published:2021-08-09

摘要: 目的:观察1,25(OH)2D3在脊柱结核治疗中对患者免疫功能的调节作用。方法:2016年1月至2019年12月在浙江省中西医结合医院骨科就诊,诊断为脊柱结核,按照3HRZE/15HRE方案抗结核治疗的患者随机分为治疗组和对照组。对照组常规抗结核治疗,治疗组在此基础上加用1,25(OH)2D3软胶囊。分别观察治疗后4周、8周两组患者血清1,25(OH)2D3、人γ干扰素(IFN-γ)、白介素(IL)-10含量和血T淋巴细胞亚群占比的变化;分析治疗组1,25(OH)2D3与各指标之间相关性。结果:治疗后4周、8周,治疗组血清1,25(OH)2D3含量分别为(31.08±10.30)、(26.12±6.66) pg/mL,高于对照组的(26.50±8.70)、(21.29±6.82)pg/mL;治疗组血清IFN-γ含量分别为(19.85±5.12)、(22.14±6.83) pg/mL,高于对照组的(16.08±5.16)、(17.03±5.34) pg/mL;治疗后8周,治疗组血清IL-10含量为(19.18±5.46) pg/mL,低于对照组(21.92±6.03) pg/mL;治疗组血CD4+、CD4+/CD8+水平分别为(43.48±9.39)%、(1.88±0.57),高于对照组(39.05±8.71)%、(1.58±0.46);治疗组1,25(OH)2D3水平与CD4+、CD4+/CD8+、IFN-γ水平呈正相关,与CD8+、IL-10水平呈负相关。结论:脊柱结核患者在治疗中补充1,25(OH)2D3是有必要的,可以提高患者血1,25(OH)2D3的含量,改善免疫功能,增强抗结核的能力。

关键词: 结核, 脊柱, 25-羟化维生素D3, 1-α-羟化酶, 免疫调节, T淋巴细胞亚群

Abstract: AIM: To observe the immunomodulatory effect of 1,25(OH)2D3 in the treatment of patients with spinal tuberculosis. METHODS: Patients diagnosed as spinal tuberculosis and treated according to the anti-tuberculosis regimen of 3HRZE/15HRE in the department of orthopedics, Zhejiang Integrated Chinese and Western Medicine Hospital from January 2016 to December 2019 were randomly divided into treatment group and control group. The control group was treated with routine therapy, while the treatment group was given 1,25(OH)2D3 capsule additionally. Changes of 1,25(OH)2D3, IFN-γ, IL-10 in the serum and the proportion of T-lymphocyte subsets in the blood of the two groups were observed at 4 and 8 weeks after treatment; the correlation between 1,25(OH)2D3 and other indexes of the treatment group was analyzed. RESULTS: At 4th and 8th weeks after treatment, the serum 1,25(OH)2D3 levels in the treatment group were (31.08±10.30), (26.12±6.66) pg/mL, higher than those in the control group (26.50±8.70), (21.29±6.82) pg/mL. The serum IFN-γ levels in the treatment group were (19.85±5.12), (22.14±6.83) pg/mL, higher than those in the control group (16.08±5.16), (17.03±5.34) pg/mL. At 8th weeks after treatment, the serum IL-10 levels in the treatment group was (19.18±5.46) pg/mL, lower than that in the control group (21.92±6.03) pg/mL. The levels of CD4+ and CD4+/CD8+ in the treatment group were (43.48±9.39)% and (1.88±0.57), higher than those in the control group (39.05±8.71)% and (1.58±0.46). In the treatment group, 1,25(OH)2D3 levels were positively correlated with CD4+, CD4+/CD8+, IFN-γ, and negatively correlated with CD8+, IL-10. CONCLUSION: It is necessary to supplement 1,25(OH)2D3 in the treatment of spinal tuberculosis. It can increase the level of 1,25(OH)2D3 in the blood, improve the immune function and enhance the ability of anti tuberculosis.

Key words: tuberculosis, spinal, 25-Hydroxyvitamin D3, 1-alpha-Hydroxylase, immunomodulation, T-lymphocyte subsets

中图分类号: